G-Quadruplex binding enantiomers show chiral selective interactions with human telomere

Nucleic Acids Research

Volumn 42, Issue 6, 2014, Pages 3792-3802

  Wang, Jiasi ^a,b   Chen, Yong ^a,b,c   Ren, Jinsong ^a,b   Zhao, Chuanqi ^a,b   Qu, Xiaogang ^a,b  

^a CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; CELL AGING; CELL LINE, TUMOR; CELL PROLIFERATION; COORDINATION COMPLEXES; DNA; DNA DAMAGE; G-QUADRUPLEXES; HUMANS; ISOMERISM; MCF-7 CELLS; TELOMERE; TELOMERE-BINDING PROTEINS;

EID: 84898980574     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkt1354     Document Type: Article

References (73)

1. de Lange, T. (2009) How telomeres solve the end-protection problem. Science, 326, 948-952.
2. Cesare, A. J. and Karlseder, J. (2012) A three-state model of telomere control over human proliferative boundaries. Curr. Opin. Cell Biol., 24, 731-738.
3. de Lange, T. (2004) T-loops and the origin of telomeres. Nat. Rev. Mol. Cell Biol., 5, 323-329.
4. Neidle, S. and Parkinson, G. N. (2003) The structure of telomeric DN A. Curr. Opin. Struct. Biol., 13, 275-283.
5. De Lange, T. (2005) Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev., 19, 2100-2110.
6. Karlseder, J., Broccoli, D., Dai, Y., Hardy, S. and de Lange, T. (1999) p53-and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science, 283, 1321-1325.
7. Smogorzewska, A., van Steensel, B., Bianchi, A., Oelmann, S., Schaefer, M. R., Schnapp, G. and de Lange, T. (2000) Control of human telomere length by TRF1 and TRF2. Mol. Cell. Biol., 20, 1659-1668.
8. d'Adda di, F., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., von Zglinicki, T., Saretzki, G., Carter, N. P. and Jackson, S. P. (2003) A DNA damage checkpoint response in telomere-initiated senescence. Nature, 426, 194-198.
9. Takai, H., Smogorzewska, A. and de Lange, T. (2003) DNA damage foci at dysfunctional telomeres. Curr. Biol., 13, 1549-1556.
10. Herbig, U., Jobling, W. A., Chen, B. P. C., Chen, D. J. and Sedivy, J. M. (2004) Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21CIP1, but not p16INK4a. Mol. Cell, 14, 501-513.
11. Sfeir, A., Kabir, S., van Overbeek, M., Celli, G. B. and de Lange, T. (2010) Loss of Rap1 induces telomere recombination in the absence of NHEJ or a DNA damage signal. Science, 327, 1657-1661.
12. Denchi, E. L. and de Lange, T. (2007) Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature, 448, 1068-1071.
13. Hockemeyer, D., Sfeir, A. J., Shay, J. W., Wright, W. E. and de Lange, T. (2005) POT1 protects telomeres from a transient DNA damage response and determines how human chromosomes end. EMBO J., 24, 2667-2678.
14. Sfeir, A. and de Lange, T. (2012) Removal of shelterin reveals the telomere end-protection problem. Science, 336, 593-597.
15. Artandi, S. E. and DePinho, R. A. (2010) Telomeres and telomerase in cancer. Carcinogenesis, 31, 9-18.
16. Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L., Coviello, G. M., Wright, W. E., Weinrich, S. L. and Shay, J. W. (1994) Specific association of human telomerase activity with immortal cells and cancer. Science, 266, 2011-2015.
17. Kelland, L. (2007) Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway. Clin. Cancer Res., 13, 4960-4963.
18. Sekaran, V., Soares, J. and Jarstfer, M. B. (2013) Telomere maintenance as a target for drug discovery. J. Med. Chem., 57, 521-538.
19. Herbert, B. S., Gellert, G. C., Hochreiter, A., Pongracz, K., Wright, W. E., Zielinska, D., Chin, A. C., Harley, C. B., Shay, J. W. and Gryaznov, S. M. (2005) Lipid modification of GRN163, an N30! P50 thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene, 24, 5262-5268.
20. El-Daly, H., Kull, M., Zimmermann, S., Pantic, M., Waller, C. F. and Martens, U. M. (2005) Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood, 105, 1742-1749.
21. Asai, A., Oshima, Y., Yamamoto, Y., Uochi, T. A., Kusaka, H., Akinaga, S., Yamashita, Y., Pongracz, K., Pruzan, R. and Wunder, E. (2003) A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res., 63, 3931-3939.
22. Bechter, O. E., Zou, Y., Walker, W., Wright, W. E. and Shay, J. W. (2004) Telomeric recombination in mismatch repair deficient human colon cancer cells after telomerase inhibition. Cancer Res., 64, 3444-3451.
23. Hu, J., Hwang, S. S., Liesa, M., Gan, B., Sahin, E., Jaskelioff, M., Ding, Z., Ying, H., Boutin, A. T. and Zhang, H. (2012) Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell, 148, 651-663.
24. Zahler, A. M., Williamson, J. R., Cech, T. R. and Prescott, D. M. (1991) Inhibition of telomerase by G-quartet DMA structures. Nature, 350, 718-720.
25. Sun, D., Thompson, B., Cathers, B. E., Salazar, M., Kerwin, S. M., Trent, J. O., Jenkins, T. C., Neidle, S. and Hurley, L. H. (1997) Inhibition of human telomerase by a G-quadruplex-interactive compound. J. Med. Chem., 40, 2113-2116.
26. Mergny, J. L. and Helene, C. (1998) G-quadruplex DNA: a target for drug design. Nat. Med., 4, 1366-1367.
27. Rezler, E. M., Bearss, D. J. and Hurley, L. H. (2003) Telomere inhibition and telomere disruption as processes for drug targeting. Annu. Rev. Pharmacol. Toxicol., 43, 359-379.
28. Chaires, J. B. and Mergny, J. L. (2008) Targeting DN A. Biochimie, 90, 973-975.
29. Balasubramanian, S. and Neidle, S. (2009) G-quadruplex nucleic acids as therapeutic targets. Curr. Opin. Chem. Biol., 13, 345-353.
30. Riou, J. F. (2004) G-quadruplex interacting agents targeting the telomeric G-overhang are more than simple telomerase inhibitors. Curr. Med. Chem. Anticancer Agents, 4, 439-443.
31. Neidle, S. (2010) Human telomeric G-quadruplex: the current status of telomeric G-quadruplexes as therapeutic targets in human cancer. FEBS J., 277, 1118-1125.
32. Kim, M. Y., Vankayalapati, H., Shin-ya, K., Wierzba, K. and Hurley, L. H. (2002) Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular G-quadruplex. J. Am. Chem. Soc., 124, 2098-2099.
33. Tauchi, T., Shin-ya, K., Sashida, G., Sumi, M., Okabe, S., Ohyashiki, J. H. and Ohyashiki, K. (2006) Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia. Oncogene, 25, 5719-5725.
34. Gowan, S. M., Harrison, J. R., Patterson, L., Valenti, M., Read, M. A., Neidle, S. and Kelland, L. R. (2002) A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol. Pharmacol., 61, 1154-1162.
35. Burger, A. M., Dai, F., Schultes, C. M., Reszka, A. P., Moore, M. J., Double, J. A. and Neidle, S. (2005) The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res., 65, 1489-1496.
36. Leonetti, C., Amodei, S., D'Angelo, C., Rizzo, A., Benassi, B., Antonelli, A., Elli, R., Stevens, M. F., D'Incalci, M., Zupi, G. et al. (2004) Biological activity of the G-quadruplex ligand RHPS4 (3,11-difluoro-6,8,13- trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate) is associated with telomere capping alteration. Mol. Pharmacol., 66, 1138-1146.
37. Leonetti, C., Scarsella, M., Riggio, G., Rizzo, A., Salvati, E., D'Incalci, M., Staszewsky, L., Frapolli, R., Stevens, M. F., Stoppacciaro, A. et al. (2008) G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors. Clin. Cancer Res., 14, 7284-7291.
38. Yu, Q., Liu, Y., Wang, C., Sun, D., Yang, X., Liu, Y. and Liu, J. (2012) Chiral ruthenium(II) polypyridyl complexes: stabilization of G-quadruplex DNA, inhibition of telomerase activity and cellular uptake. PLos One, 7, e50902.
39. Tauchi, T., Shin-Ya, K., Sashida, G., Sumi, M., Nakajima, A., Shimamoto, T., Ohyashiki, J. H. and Ohyashiki, K. (2003) Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways. Oncogene, 22, 5338-5347.
40. Rodriguez, R., Pantoş, G. D., Gonçalves, D. P. N., Sanders, J. K. M. and Balasubramanian, S. (2007) Ligand-driven g-quadruplex conformational switching by using an unusual mode of interaction. Angew. Chem. Int. Ed., 46, 5405-5407.
41. Haudecoeur, R., Stefan, L., Denat, F. and Monchaud, D. (2012) A model of smart G-quadruplex ligand. J. Am. Chem. Soc., 135, 550-553.
42. Shinohara, K. I., Sannohe, Y., Kaieda, S., Tanaka, K. I., Osuga, H., Tahara, H., Xu, Y., Kawase, T., Bando, T. and Sugiyama, H. (2010) A chiral wedge molecule inhibits telomerase activity. J. Am. Chem. Soc., 132, 3778-3782.
43. Monchaud, D. and Teulade-Fichou, M. P. (2008) A hitchhiker's guide to G-quadruplex ligands. Org. Biomol. Chem., 6, 627-636.
44. Jain, K. A. and Bhattacharya, S. (2012) Recent developments in the chemistry and biology of G-quadruplexes with reference to the DNA groove binders. Curr. Pharm. Des., 18, 1917-1933.
45. Ragazzon, P. and Chaires, J. B. (2007) Use of competition dialysis in the discovery of G-quadruplex selective ligands. Methods, 43, 313-323.
46. Yu, H., Wang, X., Fu, M., Ren, J. and Qu, X. (2008) Chiral metallosupramolecular complexes selectively recognize human telomeric G-quadruplex DN A. Nucleic Acids Res., 36, 5695-5703.
47. Yu, H., Zhao, C., Chen, Y., Fu, M., Ren, J. and Qu, X. (2010) DNA loop sequence as the determinant for chiral supramolecular compound G-quadruplex selectivity. J. Med. Chem., 53, 492-498.
48. Zhao, C., Geng, J., Feng, L., Ren, J. and Qu, X. (2011) Chiral metallo-supramolecular complexes selectively induce human telomeric G-quadruplex formation under salt-deficient conditions. Chem. Eur. J., 17, 8209-8215.
49. Meistermann, I., Moreno, V., Prieto, M. J., Moldrheim, E., Sletten, E., Khalid, S., Rodger, P. M., Peberdy, J. C., Isaac, C. J., Rodger, A. et al. (2002) Intramolecular DNA coiling mediated by metallosupramolecular cylinders: differential binding of P and M helical enantiomers. Proc. Natl Acad. Sci. USA, 99, 5069-5074.
50. Hannon, M. J., Meistermann, I., Isaac, C. J., Blomme, C., Aldrich-Wright, J. R. and Rodger, A. (2001) Paper: a cheap yet effective chiral stationary phase for chromatographic resolution of metallosupramolecular helicates. Chem. Commun., 1078-1079.
51. Chen, Y., Qu, K., Zhao, C., Wu, L., Ren, J., Wang, J. and Qu, X. (2012) Insights into the biomedical effects of carboxylated singlewall carbon nanotubes on telomerase and telomeres. Nat. Commun., 3, 1074.
52. Ward, I. M. and Chen, J. (2001) Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. J. Biol. Chem., 276, 47759-47762.
53. Salvati, E., Leonetti, C., Rizzo, A., Scarsella, M., Mottolese, M., Galati, R., Sperduti, I., Stevens, M. F., D'Incalci, M. and Blasco, M. (2007) Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. J. Clin. Invest., 117, 3236-3247.
54. Gomez, D., Wenner, T., Brassart, B., Douarre, C., O'Donohue, M. F., El Khoury, V., Shin-Ya, K., Morjani, H., Trentesaux, C. and Riou, J. F. (2006) Telomestatin-induced telomere uncapping is modulated by POT1 through G-overhang extension in HT1080 human tumor cells. J. Biol. Chem., 281, 38721-38729.
55. Tahara, H., Shin-Ya, K., Seimiya, H., Yamada, H., Tsuruo, T. and Ide, T. (2006) G-Quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 30 telomeric overhang in cancer cells. Oncogene, 25, 1955-1966.
56. Loayza, D. and de Lange, T. (2003) POT1 as a terminal transducer of TRF1 telomere length control. Nature, 423, 1013-1018.
57. Biroccio, A., Rizzo, A., Elli, R., Koering, C. E., Belleville, A., Benassi, B., Leonetti, C., Stevens, M. F. G., D'Incalci, M., Zupi, G. et al. (2006) TRF2 inhibition triggers apoptosis and reduces tumourigenicity of human melanoma cells. Eur. J. Cancer, 42, 1881-1888.
58. van Steensel, B., Smogorzewska, A. and de Lange, T. (1998) TRF2 protects human telomeres from end-to-end fusions. Cell, 92, 401-413.
59. Seimiya, H., Sawada, H., Muramatsu, Y., Shimizu, M., Ohko, K., Yamane, K. and Tsuruo, T. (2000) Involvement of 14-3-3 proteins in nuclear localization of telomerase. EMBO J., 19, 2652-2661.
60. Akiyama, M., Hideshima, T., Hayashi, T., Tai, Y. T., Mitsiades, C. S., Mitsiades, N., Chauhan, D., Richardson, P., Munshi, N. C. and Anderson, K. C. (2003) Nuclear factor-kB p65 mediates tumor necrosis factor a-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res., 63, 18-21.
61. Liu, K., Hodes, R. J. and Weng, N. P. (2001) Cutting edge: telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation. J. Immunol., 166, 4826-4830.
62. Liao, C. H., Hsiao, Y. M., Sheu, G. T., Chang, J. T., Wang, P. H., Wu, M. F., Shieh, G. J., Hsu, C. P. and Ko, J. L. (2007) Nuclear translocation of telomerase reverse transcriptase and calcium signaling in repression of telomerase activity in human lung cancer cells by fungal immunomodulatory protein from Ganoderma tsugae. Biochem. Pharmacol., 74, 1541-1554.
63. Haendeler, J., Hoffmann, J., Brandes, R. P., Zeiher, A. M. and Dimmeler, S. (2003) Hydrogen peroxide triggers nuclear export of telomerase reverse transcriptase via Src kinase family-dependent phosphorylation of tyrosine 707. Mol. Cell Biol., 23, 4598-4610.
64. Tahara, H., Kusunoki, M., Yamanaka, Y., Matsumura, S. and Ide, T. (2005) G-tail telomere HPA: simple measurement of human single-stranded telomeric overhangs. Nat. Methods, 2, 829-831.
65. Karlseder, J., Smogorzewska, A. and de Lange, T. (2002) Senescence induced by altered telomere state, not telomere loss. Science, 295, 2446-2449.
66. Veldman, T., Etheridge, K. T. and Counter, C. M. (2004) Loss of hPot1 function leads to telomere instability and a cut-like phenotype. Curr. Biol., 14, 2264-2270.
67. Zaug, A. J., Podell, E. R. and Cech, T. R. (2005) Human POT1 disrupts telomeric G-quadruplexes allowing telomerase extension in vitro. Proc. Natl Acad. Sci. USA, 102, 10864-10869.
68. Howson, S. E., Bolhuis, A., Brabec, V., Clarkson, G. J., Malina, J., Rodger, A. and Scott, P. (2011) Optically pure, water-stable metallo-helical 'flexicate'assemblies with antibiotic activity. Nat. Chem., 4, 31-36.
69. Brabec, V., Howson, S. E., Kaner, R. A., Lord, R. M., Malina, J., Phillips, R. M., Abdallah, Q. M., McGowan, P. C., Rodger, A. and Scott, P. (2013) Metallohelices with activity against cisplatinresistant cancer cells; does the mechanism involve DNA binding? Chem. Sci., 4, 4407-4416.
70. Hanaoka, S., Nagadoi, A. and Nishimura, Y. (2005) Comparison between TRF2 and TRF1 of their telomeric DNA-bound structures and DNA-binding activities. Protein Sci., 14, 119-130.
71. Phatak, P., Cookson, J. C., Dai, F., Smith, V., Gartenhaus, R. B., Stevens, M. F. and Burger, A. M. (2007) Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism. Br. J. Cancer, 96, 1223-1233.
72. Huffman, K. E., Levene, S. D., Tesmer, V. M., Shay, J. W. and Wright, W. E. (2000) Telomere shortening is proportional to the size of the G-rich telomeric 30-overhang. J. Biol. Chem., 275, 19719-19722.
73. Rahman, R., Forsyth, N. R. and Cui, W. (2008) Telomeric 30-overhang length is associated with the size of telomeres. Exp. Gerontol., 43, 258-265.